---

$2.00

+0.0350 ( +1.79% ) 452.7K

Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.

Type: All Buy Sale Start date: End date: Filter Reset

Date	Type	Amount Purchased	Purchaser
2025-08-12	Buy	129000.00	Schwartz Aharon
2024-04-03	Sale	-263960.00	Bashan Dror
2023-10-20	Buy	48387.00	Bashan Dror
2023-10-03	Sale	-61676.00	Schwartz Aharon
2023-10-03	Sale	-61676.00	Bar-Shalev Amos
2023-10-03	Sale	-61676.00	Melincoff Gwen A
2023-10-03	Sale	-61676.00	Boudes Pol F
2023-10-03	Sale	-61676.00	Ben Zvi Shmuel
2023-09-15	Sale	-85715.00	Forster Eliot
2023-08-17	Sale	-800000.00	Bashan Dror